JP2009525277A - 軟組織石灰化の回復、予防、遅延または安定化方法 - Google Patents
軟組織石灰化の回復、予防、遅延または安定化方法 Download PDFInfo
- Publication number
- JP2009525277A JP2009525277A JP2008552435A JP2008552435A JP2009525277A JP 2009525277 A JP2009525277 A JP 2009525277A JP 2008552435 A JP2008552435 A JP 2008552435A JP 2008552435 A JP2008552435 A JP 2008552435A JP 2009525277 A JP2009525277 A JP 2009525277A
- Authority
- JP
- Japan
- Prior art keywords
- ferric
- organic
- subject
- soft tissue
- organic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002037 soft tissue calcification Effects 0.000 title claims abstract description 37
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims abstract description 64
- 229960002413 ferric citrate Drugs 0.000 claims abstract description 62
- 150000002894 organic compounds Chemical class 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 39
- 210000001508 eye Anatomy 0.000 claims abstract description 31
- 208000020832 chronic kidney disease Diseases 0.000 claims abstract description 26
- 210000003734 kidney Anatomy 0.000 claims abstract description 19
- 210000003709 heart valve Anatomy 0.000 claims abstract description 9
- 210000004072 lung Anatomy 0.000 claims abstract description 8
- 210000004165 myocardium Anatomy 0.000 claims abstract description 8
- 210000003491 skin Anatomy 0.000 claims abstract description 8
- 210000002565 arteriole Anatomy 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims description 36
- 150000007524 organic acids Chemical class 0.000 claims description 29
- 239000002244 precipitate Substances 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 238000000502 dialysis Methods 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 16
- 238000004090 dissolution Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 15
- 201000000523 end stage renal failure Diseases 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 13
- -1 troche Substances 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 208000028208 end stage renal disease Diseases 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 210000004872 soft tissue Anatomy 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 239000007937 lozenge Substances 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 229940044631 ferric chloride hexahydrate Drugs 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical group O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 229910000462 iron(III) oxide hydroxide Inorganic materials 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 238000011285 therapeutic regimen Methods 0.000 claims description 3
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 230000001934 delay Effects 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 abstract description 5
- 210000001503 joint Anatomy 0.000 abstract description 5
- 210000000748 cardiovascular system Anatomy 0.000 abstract description 3
- 210000001835 viscera Anatomy 0.000 abstract description 3
- 208000004434 Calcinosis Diseases 0.000 description 31
- 230000002308 calcification Effects 0.000 description 30
- 201000001891 corneal deposit Diseases 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 21
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 239000011575 calcium Substances 0.000 description 9
- 210000004087 cornea Anatomy 0.000 description 9
- 229940109239 creatinine Drugs 0.000 description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 8
- 208000005475 Vascular calcification Diseases 0.000 description 8
- 229960004887 ferric hydroxide Drugs 0.000 description 8
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 102000003982 Parathyroid hormone Human genes 0.000 description 6
- 108090000445 Parathyroid hormone Proteins 0.000 description 6
- 239000000199 parathyroid hormone Substances 0.000 description 6
- 229960001319 parathyroid hormone Drugs 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000015096 spirit Nutrition 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 201000005991 hyperphosphatemia Diseases 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000003708 edge detection Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000121 hypercalcemic effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 208000027361 mineral metabolism disease Diseases 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76325306P | 2006-01-30 | 2006-01-30 | |
| PCT/US2006/032385 WO2007022435A2 (en) | 2005-08-18 | 2006-08-18 | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
| PCT/US2007/002157 WO2007089577A2 (en) | 2006-01-30 | 2007-01-26 | Method of reversing, preventing, delaying or stabilizing soft tissue calcification |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013142389A Division JP6154226B2 (ja) | 2006-01-30 | 2013-07-08 | 軟組織石灰化の回復、予防、遅延または安定化方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2009525277A true JP2009525277A (ja) | 2009-07-09 |
Family
ID=39739742
Family Applications (14)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552435A Pending JP2009525277A (ja) | 2006-01-30 | 2007-01-26 | 軟組織石灰化の回復、予防、遅延または安定化方法 |
| JP2008552431A Pending JP2009525276A (ja) | 2006-01-30 | 2007-01-26 | 慢性腎疾患の治療法 |
| JP2013142389A Active JP6154226B2 (ja) | 2006-01-30 | 2013-07-08 | 軟組織石灰化の回復、予防、遅延または安定化方法 |
| JP2013142517A Pending JP2013227333A (ja) | 2006-01-30 | 2013-07-08 | 慢性腎疾患の治療法 |
| JP2014157464A Active JP6368186B2 (ja) | 2006-01-30 | 2014-08-01 | 慢性腎疾患の治療法 |
| JP2015180311A Active JP6632842B2 (ja) | 2006-01-30 | 2015-09-14 | 慢性腎疾患の治療法 |
| JP2016176150A Pending JP2017036289A (ja) | 2006-01-30 | 2016-09-09 | 慢性腎疾患の治療法 |
| JP2016252260A Pending JP2017095477A (ja) | 2006-01-30 | 2016-12-27 | 慢性腎疾患の治療法 |
| JP2017041248A Active JP6239169B2 (ja) | 2006-01-30 | 2017-03-06 | 軟組織石灰化の回復、予防、遅延または安定化方法 |
| JP2018006046A Pending JP2018109001A (ja) | 2006-01-30 | 2018-01-18 | 慢性腎疾患の治療法 |
| JP2019112469A Pending JP2019194212A (ja) | 2006-01-30 | 2019-06-18 | 慢性腎疾患の治療法 |
| JP2021159648A Pending JP2022020633A (ja) | 2006-01-30 | 2021-09-29 | 慢性腎疾患の治療法 |
| JP2023015069A Pending JP2023055886A (ja) | 2006-01-30 | 2023-02-03 | 慢性腎疾患の治療法 |
| JP2024168044A Pending JP2025016448A (ja) | 2006-01-30 | 2024-09-27 | 慢性腎疾患の治療法 |
Family Applications After (13)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552431A Pending JP2009525276A (ja) | 2006-01-30 | 2007-01-26 | 慢性腎疾患の治療法 |
| JP2013142389A Active JP6154226B2 (ja) | 2006-01-30 | 2013-07-08 | 軟組織石灰化の回復、予防、遅延または安定化方法 |
| JP2013142517A Pending JP2013227333A (ja) | 2006-01-30 | 2013-07-08 | 慢性腎疾患の治療法 |
| JP2014157464A Active JP6368186B2 (ja) | 2006-01-30 | 2014-08-01 | 慢性腎疾患の治療法 |
| JP2015180311A Active JP6632842B2 (ja) | 2006-01-30 | 2015-09-14 | 慢性腎疾患の治療法 |
| JP2016176150A Pending JP2017036289A (ja) | 2006-01-30 | 2016-09-09 | 慢性腎疾患の治療法 |
| JP2016252260A Pending JP2017095477A (ja) | 2006-01-30 | 2016-12-27 | 慢性腎疾患の治療法 |
| JP2017041248A Active JP6239169B2 (ja) | 2006-01-30 | 2017-03-06 | 軟組織石灰化の回復、予防、遅延または安定化方法 |
| JP2018006046A Pending JP2018109001A (ja) | 2006-01-30 | 2018-01-18 | 慢性腎疾患の治療法 |
| JP2019112469A Pending JP2019194212A (ja) | 2006-01-30 | 2019-06-18 | 慢性腎疾患の治療法 |
| JP2021159648A Pending JP2022020633A (ja) | 2006-01-30 | 2021-09-29 | 慢性腎疾患の治療法 |
| JP2023015069A Pending JP2023055886A (ja) | 2006-01-30 | 2023-02-03 | 慢性腎疾患の治療法 |
| JP2024168044A Pending JP2025016448A (ja) | 2006-01-30 | 2024-09-27 | 慢性腎疾患の治療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US9750715B2 (https=) |
| EP (3) | EP3066923B1 (https=) |
| JP (14) | JP2009525277A (https=) |
| CN (4) | CN101374416A (https=) |
| AU (2) | AU2007210090B2 (https=) |
| CA (2) | CA2640763C (https=) |
| DK (1) | DK1978807T3 (https=) |
| ES (2) | ES2699447T3 (https=) |
| HU (1) | HUE028029T2 (https=) |
| IL (2) | IL192545A (https=) |
| WO (2) | WO2007089577A2 (https=) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012099139A1 (ja) * | 2011-01-18 | 2012-07-26 | 日本たばこ産業株式会社 | β酸化水酸化鉄を実質的に含まないクエン酸第二鉄 |
| JP2016535780A (ja) * | 2013-11-04 | 2016-11-17 | ケリク バイオファーマシューティカルス， インコーポレーテッド | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 |
| JP2020528888A (ja) * | 2017-07-26 | 2020-10-01 | ファーマヌトゥラ・エッセ・ピ・ア | 心血管器官の病態の予防及び処置における使用のための組成物 |
| US12246036B2 (en) | 2017-08-02 | 2025-03-11 | Pharmanutra S.P.A. | Composition for use in the prevention and in the treatment of iron deficiency |
| US12297406B2 (en) | 2019-05-27 | 2025-05-13 | Alesco S.R.L. | Method for preparing a composition comprising cetylated fatty acids |
| US12383525B2 (en) | 2019-05-27 | 2025-08-12 | Pharmanutra S.P.A. | Compositions comprising cetylated fatty acids and use thereof for the treatment of arthritis and joint inflammatory conditions |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220144872A1 (en) * | 2003-02-19 | 2022-05-12 | Panion & Bf Biotech Inc. | Pharmaceutical-Grade Ferric Organic Compounds, Uses Thereof and Methods of Making Same |
| US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| TWI335218B (en) * | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| EP3066923B1 (en) | 2006-01-30 | 2025-11-05 | Panion & BF Biotech Inc. | Method of treating chronic kidney disease |
| US7658952B2 (en) | 2007-10-11 | 2010-02-09 | Baxter International Inc. | Dialysis solutions containing pyrophosphates |
| EP2340821B1 (en) | 2008-10-27 | 2017-01-25 | SBI Pharmaceuticals Co., Ltd. | Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative of 5-aminolevulinic acid as active ingredient |
| US8178709B2 (en) * | 2009-07-21 | 2012-05-15 | Biolink Life Sciences, Inc. | Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof |
| CN108938585A (zh) | 2009-07-21 | 2018-12-07 | 凯克斯生物制药公司 | 柠檬酸铁剂型 |
| EP2594277A4 (en) * | 2010-07-07 | 2014-01-01 | Japan Tobacco Inc | TABLET WITH IRON CITRATE |
| JP2012112785A (ja) * | 2010-11-24 | 2012-06-14 | Tohoku Univ | 透析膜の評価方法 |
| SG11201408521WA (en) | 2012-06-21 | 2015-01-29 | Keryx Biopharmaceuticals Inc | Use of ferric citrate in the treatment of chronic kidney disease patients |
| JP6348495B2 (ja) * | 2012-09-04 | 2018-06-27 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | シトレートに富むカルシウム・マグネシウム補助剤およびその使用 |
| EP3157516A4 (en) * | 2014-06-22 | 2017-12-13 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| JP2018526349A (ja) * | 2015-08-05 | 2018-09-13 | ルピン・リミテッド | 医薬品グレードのクエン酸第二鉄の調製のためのプロセス |
| WO2018193648A1 (ja) * | 2017-04-18 | 2018-10-25 | 国立大学法人東北大学 | アルカリ性化剤による血液浄化 |
| JP7578234B2 (ja) * | 2017-04-18 | 2024-11-06 | 国立大学法人東北大学 | アルカリ性化剤による血液浄化 |
| JP7219898B2 (ja) * | 2017-04-18 | 2023-02-09 | 国立大学法人東北大学 | アルカリ性化剤による血液浄化 |
| EP3737938B1 (en) * | 2018-01-12 | 2023-10-25 | Mayo Foundation for Medical Education and Research | Systems and methods for the detection and quantification of ammonia and ammonium in fluids |
| WO2020018554A1 (en) * | 2018-07-17 | 2020-01-23 | The Regents Of The University Of California | Methods of treating renal disease |
| KR20210076008A (ko) * | 2018-10-17 | 2021-06-23 | 교토후고리츠다이가쿠호진 | 당뇨병 신증에 있어서의 신장 섬유화 억제제 |
| EP3868371A4 (en) * | 2018-10-17 | 2022-11-02 | Tohoku University | Novel pharmaceutical composition |
| US20220202752A1 (en) * | 2019-04-28 | 2022-06-30 | Tohoku University | Novel pharmaceutical composition |
| JP7696926B2 (ja) * | 2020-05-13 | 2025-06-23 | コンパニー ゼネラール デ エタブリッスマン ミシュラン | 濡れた地面上の寿命末期グリップが改善されたタイヤ |
| AU2022227671A1 (en) * | 2021-02-24 | 2023-09-07 | MoxxiTech, LLC | Compositions and methods for treating canine parvovirus infection |
| CN117999069A (zh) | 2021-05-27 | 2024-05-07 | 凯克斯生物制药公司 | 柠檬酸铁的儿科调配物 |
| KR102623739B1 (ko) * | 2022-07-28 | 2024-01-11 | 주식회사 페라메드 | 시트르산과 철을 포함하는 착화합물 및 그를 포함하는 식품 조성물 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04503356A (ja) * | 1989-02-17 | 1992-06-18 | バクスター インターナショナル インコーポレーテッド | 生充填移植片の石灰化軽減 |
| JP2001506262A (ja) * | 1996-12-16 | 2001-05-15 | チェン シン スー | 腎不全の治療方法 |
| JP2002501787A (ja) * | 1998-02-02 | 2002-01-22 | セント・ジュード・メディカル・インコーポレーテッド | 抗石灰化医療物品 |
| CN1446790A (zh) * | 2002-09-09 | 2003-10-08 | 苏荣仁 | 药用级枸橼酸铁及其制备方法 |
| WO2004074444A2 (en) * | 2003-02-19 | 2004-09-02 | Globoasia Llc | Ferric organic compounds, uses thereof and methods of making same |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2081547A (en) | 1934-02-14 | 1937-05-25 | Parke Davis & Co | Therapeutic agent |
| DE1131360B (de) | 1957-11-26 | 1962-06-14 | Vitarine Company Inc | Verfahren zum Stabilisieren von waessrigen Loesungen, die neben Vitamin B noch Vitamin B und Vitamin C enthalten |
| SU142643A1 (ru) | 1961-03-25 | 1961-11-30 | В.Б. Тихомиров | Способ извлечени соединений железа из водной фазы |
| AT279048B (de) | 1967-07-04 | 1970-02-25 | Pharmazeutische Fabrik Montavit Gmbh | Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon |
| US3549614A (en) | 1967-07-13 | 1970-12-22 | Jan Zbigniew Mioduszewski | Method of manufacture of mixed complex compounds of ferric iron with hydrogenated dextran and citric acid or sodium citrate |
| GB1224589A (en) | 1969-10-06 | 1971-03-10 | Gerhard Gergely | Complex iron salts |
| US4180567A (en) | 1977-09-02 | 1979-12-25 | Pharmachem Corporation | Iron preparations and methods of making and administering the same |
| DE3228231A1 (de) | 1982-07-28 | 1984-02-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | Arzneimittel, calciummischsalze von polymeren, anionischen carbonsaeuren und/oder schwefelsaeureestern, verfahren zu ihrer herstellung und ihre verwendung |
| US5089644A (en) | 1985-01-04 | 1992-02-18 | Salutar Inc. | Preparation of oxamine complexes |
| US4851221A (en) | 1985-02-19 | 1989-07-25 | Mission Pharmacal Company | Liquid calcium supplementation from readily soluble mixtures of calcium compound and citric acid |
| IT1222654B (it) | 1987-09-14 | 1990-09-12 | Schering Ag | Complesso micellare di ferro-citrato |
| GB2212396A (en) | 1987-12-18 | 1989-07-26 | Procter & Gamble | Dietary supplement comprising calcium and delayed release coated iron |
| US5602116A (en) * | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| NL194959C (nl) | 1988-10-04 | 2003-09-02 | Otsuka Pharma Co Ltd | Preparaat voor het toedienen van ijzer. |
| US4970079A (en) | 1989-06-05 | 1990-11-13 | Purdue Research Foundation | Method and composition of oxy-iron compounds for treatment of hyperphosphatemia |
| JP2523057B2 (ja) | 1990-10-31 | 1996-08-07 | 有限会社丸吉商事 | 多重ポリ袋の製造方法及び製造装置 |
| DE4239442C2 (de) | 1992-11-24 | 2001-09-13 | Sebo Gmbh | Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten |
| JP3302178B2 (ja) | 1994-06-22 | 2002-07-15 | 日本クラウンコルク株式会社 | 合成樹脂製容器蓋 |
| JPH08198760A (ja) | 1995-01-20 | 1996-08-06 | Japan Organo Co Ltd | 経口用リン酸イオン吸着剤 |
| US20040043971A1 (en) * | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| DE19638044A1 (de) | 1996-09-18 | 1998-03-19 | Bayer Ag | Immunogene Peptide von Maul- und Klauenseuchen-Viren |
| RU2188033C2 (ru) | 1997-03-18 | 2002-08-27 | Рош Диагностикс Гмбх | Комбинированные фармацевтические препараты, содержащие эритропоэтин и препараты железа |
| US6706287B2 (en) * | 2001-05-15 | 2004-03-16 | Kibow Biotech Inc. | Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
| CN1315174A (zh) * | 2000-03-31 | 2001-10-03 | 苏荣仁 | 治疗肾衰的药物组合物 |
| US6887897B2 (en) * | 2001-07-31 | 2005-05-03 | Mission Pharmacal Company | Calcium glutarate supplement and phosphorus binder |
| KR101011373B1 (ko) | 2002-07-11 | 2011-01-28 | 비큐론 파마슈티컬스 인코포레이티드 | 항균작용을 갖는 ｎ-히드록시아미드 유도체 |
| US8093423B2 (en) * | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| KR100511227B1 (ko) | 2003-06-27 | 2005-08-31 | 박상래 | 휴대용 감시 카메라 및 이를 이용한 개인 방범 시스템 |
| TWI259772B (en) | 2003-09-04 | 2006-08-11 | Panion & Bf Biotech Inc | Medical composition comprising ferric citrate, ferric citrate in medical grade and preparation thereof, and dietary nutriment comprising ferric citrate |
| CN1600302A (zh) | 2003-09-22 | 2005-03-30 | 宝龄富锦生技股份有限公司 | 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品 |
| US6903235B2 (en) | 2003-10-08 | 2005-06-07 | Panion & Bf Biotech Inc. | Pharmaceutical-grade ferric citrate |
| JP4869229B2 (ja) * | 2004-07-27 | 2012-02-08 | シア ファーマシューティカルズ，インク． | 水酸化炭酸ランタンを用いた高リン血症を治療するための医薬組成物 |
| US7733285B2 (en) * | 2005-05-18 | 2010-06-08 | Qualcomm Incorporated | Integrated, closely spaced, high isolation, printed dipoles |
| US7904971B2 (en) * | 2005-05-19 | 2011-03-15 | Mine Safety Appliances Company | Protective padding and protective padding systems |
| NZ566743A (en) * | 2005-08-18 | 2010-07-30 | Globoasia Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
| JP4692234B2 (ja) | 2005-11-10 | 2011-06-01 | ソニー株式会社 | 変調テーブル、変調装置および方法、プログラム、並びに記録媒体 |
| UA95795C2 (ru) | 2006-01-27 | 2011-09-12 | Юниверсити Оф Массачусетс | Способ изготовления продукта из биомассы и установка по производству топлива из биомассы |
| EP3066923B1 (en) | 2006-01-30 | 2025-11-05 | Panion & BF Biotech Inc. | Method of treating chronic kidney disease |
| KR20080094013A (ko) | 2006-01-30 | 2008-10-22 | 글로보아시아 엘엘씨 | 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법 |
| CN101019848B (zh) | 2006-11-17 | 2010-09-15 | 苏荣仁 | 枸橼酸铁在制备防治血管钙化的药物中的应用 |
| WO2008147153A1 (en) | 2007-05-31 | 2008-12-04 | Lg Chem, Ltd. | Electrical connecting member of assembling type and secondary battery pack containing the same |
| JP5526466B2 (ja) | 2007-07-17 | 2014-06-18 | 株式会社大林組 | 耐火セグメントの製造方法 |
| CN101235186B (zh) | 2008-01-03 | 2010-08-11 | 中国船舶重工集团公司第七二五研究所 | 一种无溶剂可自分层固化的环氧-有机硅组合物 |
| CN108938585A (zh) | 2009-07-21 | 2018-12-07 | 凯克斯生物制药公司 | 柠檬酸铁剂型 |
-
2007
- 2007-01-26 EP EP16161784.0A patent/EP3066923B1/en active Active
- 2007-01-26 ES ES07762833T patent/ES2699447T3/es active Active
- 2007-01-26 DK DK07717051.2T patent/DK1978807T3/en active
- 2007-01-26 EP EP07762833.7A patent/EP1978808B1/en not_active Not-in-force
- 2007-01-26 EP EP07717051.2A patent/EP1978807B1/en active Active
- 2007-01-26 HU HUE07717051A patent/HUE028029T2/en unknown
- 2007-01-26 US US12/162,558 patent/US9750715B2/en active Active
- 2007-01-26 AU AU2007210090A patent/AU2007210090B2/en active Active
- 2007-01-26 US US12/162,543 patent/US20090186939A1/en not_active Abandoned
- 2007-01-26 CA CA2640763A patent/CA2640763C/en not_active Expired - Fee Related
- 2007-01-26 JP JP2008552435A patent/JP2009525277A/ja active Pending
- 2007-01-26 CN CNA2007800039832A patent/CN101374416A/zh active Pending
- 2007-01-26 CN CNA2007800039902A patent/CN101378658A/zh active Pending
- 2007-01-26 AU AU2007210096A patent/AU2007210096B2/en active Active
- 2007-01-26 CN CN201510276285.6A patent/CN105055446B/zh active Active
- 2007-01-26 WO PCT/US2007/002157 patent/WO2007089577A2/en not_active Ceased
- 2007-01-26 JP JP2008552431A patent/JP2009525276A/ja active Pending
- 2007-01-26 ES ES07717051.2T patent/ES2580127T3/es active Active
- 2007-01-26 CN CN201610003010.XA patent/CN105616397A/zh active Pending
- 2007-01-26 CA CA2640974A patent/CA2640974C/en active Active
- 2007-01-26 WO PCT/US2007/002151 patent/WO2007089571A2/en not_active Ceased
-
2008
- 2008-06-30 IL IL192545A patent/IL192545A/en active IP Right Grant
- 2008-07-28 IL IL193099A patent/IL193099A/en not_active IP Right Cessation
-
2010
- 2010-06-22 US US12/821,081 patent/US20110060041A1/en not_active Abandoned
-
2013
- 2013-07-08 JP JP2013142389A patent/JP6154226B2/ja active Active
- 2013-07-08 JP JP2013142517A patent/JP2013227333A/ja active Pending
-
2014
- 2014-08-01 JP JP2014157464A patent/JP6368186B2/ja active Active
-
2015
- 2015-09-14 JP JP2015180311A patent/JP6632842B2/ja active Active
-
2016
- 2016-09-09 JP JP2016176150A patent/JP2017036289A/ja active Pending
- 2016-12-27 JP JP2016252260A patent/JP2017095477A/ja active Pending
-
2017
- 2017-03-06 JP JP2017041248A patent/JP6239169B2/ja active Active
- 2017-09-04 US US15/694,876 patent/US9889113B2/en not_active Expired - Fee Related
- 2017-11-16 US US15/814,767 patent/US10898459B2/en active Active
-
2018
- 2018-01-18 JP JP2018006046A patent/JP2018109001A/ja active Pending
- 2018-02-12 US US15/894,544 patent/US20180235923A1/en not_active Abandoned
-
2019
- 2019-06-18 JP JP2019112469A patent/JP2019194212A/ja active Pending
-
2021
- 2021-07-29 US US17/388,361 patent/US20220193022A1/en not_active Abandoned
- 2021-09-29 JP JP2021159648A patent/JP2022020633A/ja active Pending
-
2023
- 2023-02-03 JP JP2023015069A patent/JP2023055886A/ja active Pending
-
2024
- 2024-06-14 US US18/743,657 patent/US20250144065A1/en active Pending
- 2024-09-27 JP JP2024168044A patent/JP2025016448A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04503356A (ja) * | 1989-02-17 | 1992-06-18 | バクスター インターナショナル インコーポレーテッド | 生充填移植片の石灰化軽減 |
| JP2001506262A (ja) * | 1996-12-16 | 2001-05-15 | チェン シン スー | 腎不全の治療方法 |
| JP2002501787A (ja) * | 1998-02-02 | 2002-01-22 | セント・ジュード・メディカル・インコーポレーテッド | 抗石灰化医療物品 |
| CN1446790A (zh) * | 2002-09-09 | 2003-10-08 | 苏荣仁 | 药用级枸橼酸铁及其制备方法 |
| WO2004074444A2 (en) * | 2003-02-19 | 2004-09-02 | Globoasia Llc | Ferric organic compounds, uses thereof and methods of making same |
Non-Patent Citations (9)
| Title |
|---|
| BIOMATERIALS, vol. 13, no. 6, JPN6012039146, 1992, pages 345 - 352, ISSN: 0002289239 * |
| KOBE. J. MED. SCI., vol. 32, no. 4, JPN6012068093, 1986, pages 133 - 140, ISSN: 0002423103 * |
| NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 17, JPN6012039145, 2002, pages 265 - 270, ISSN: 0002289238 * |
| PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 170, JPN6012039147, 1982, pages 321 - 327, ISSN: 0002289240 * |
| THE JOURNAL OF UROLOGY, vol. 128, JPN6012039148, 1982, pages 1372 - 1375, ISSN: 0002289241 * |
| 日本眼科紀要, vol. 33, no. 4, JPN6012068091, 1982, pages 729 - 733, ISSN: 0002423102 * |
| 日本眼科紀要, vol. 34, no. 9, JPN6012068089, 1983, pages 2110 - 2114, ISSN: 0002423101 * |
| 日本透析医会雑誌, vol. 18, no. 2, JPN6012068087, 2003, pages 101 - 106, ISSN: 0002423100 * |
| 腎と透析, vol. 48, no. 4, JPN6012068085, 2000, pages 525 - 528, ISSN: 0002423099 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019203006A (ja) * | 2011-01-18 | 2019-11-28 | 日本たばこ産業株式会社 | β酸化水酸化鉄を実質的に含まないクエン酸第二鉄 |
| WO2012099139A1 (ja) * | 2011-01-18 | 2012-07-26 | 日本たばこ産業株式会社 | β酸化水酸化鉄を実質的に含まないクエン酸第二鉄 |
| JP5944077B1 (ja) * | 2011-01-18 | 2016-07-05 | 日本たばこ産業株式会社 | β酸化水酸化鉄を実質的に含まないクエン酸第二鉄 |
| JP2016145232A (ja) * | 2011-01-18 | 2016-08-12 | 日本たばこ産業株式会社 | β酸化水酸化鉄を実質的に含まないクエン酸第二鉄 |
| JP2025065256A (ja) * | 2011-01-18 | 2025-04-17 | 日本たばこ産業株式会社 | β酸化水酸化鉄を実質的に含まないクエン酸第二鉄 |
| JP2018009027A (ja) * | 2011-01-18 | 2018-01-18 | 日本たばこ産業株式会社 | β酸化水酸化鉄を実質的に含まないクエン酸第二鉄 |
| JP2012162522A (ja) * | 2011-01-18 | 2012-08-30 | Japan Tobacco Inc | β酸化水酸化鉄を実質的に含まないクエン酸第二鉄 |
| JP2023095949A (ja) * | 2011-01-18 | 2023-07-06 | 日本たばこ産業株式会社 | β酸化水酸化鉄を実質的に含まないクエン酸第二鉄 |
| JP2016535780A (ja) * | 2013-11-04 | 2016-11-17 | ケリク バイオファーマシューティカルス， インコーポレーテッド | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 |
| JP2019206562A (ja) * | 2013-11-04 | 2019-12-05 | ケリク バイオファーマシューティカルス， インコーポレーテッド | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 |
| JP2023090869A (ja) * | 2017-07-26 | 2023-06-29 | ファーマヌトゥラ・エッセ・ピ・ア | 心血管器官の病態の予防及び処置における使用のための組成物 |
| JP2020528888A (ja) * | 2017-07-26 | 2020-10-01 | ファーマヌトゥラ・エッセ・ピ・ア | 心血管器官の病態の予防及び処置における使用のための組成物 |
| US12246036B2 (en) | 2017-08-02 | 2025-03-11 | Pharmanutra S.P.A. | Composition for use in the prevention and in the treatment of iron deficiency |
| US12297406B2 (en) | 2019-05-27 | 2025-05-13 | Alesco S.R.L. | Method for preparing a composition comprising cetylated fatty acids |
| US12383525B2 (en) | 2019-05-27 | 2025-08-12 | Pharmanutra S.P.A. | Compositions comprising cetylated fatty acids and use thereof for the treatment of arthritis and joint inflammatory conditions |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6239169B2 (ja) | 軟組織石灰化の回復、予防、遅延または安定化方法 | |
| Nesterova et al. | Nephropathic cystinosis: late complications of a multisystemic disease | |
| Mendoza et al. | Hepatic myelopathy: a rare complication of portacaval shunt | |
| EA032779B1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| KR20080094013A (ko) | 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법 | |
| US11033498B2 (en) | Solid oral sulfate salt formulations for cleaning a colon and methods of using same | |
| Gauden et al. | MRI safety; nephrogenic systemic fibrosis and other risks | |
| CN111658641A (zh) | 慢性肾病的发展抑制或改善剂 | |
| AU2020378982A1 (en) | Anti-C5 agent for treatment of dry age-related macular degeneration (AMD) or geographic atrophy secondary to dry AMD | |
| WO2018084959A2 (en) | Pharmaceutical quality strontium l-lactate | |
| Jacob et al. | Magnetic resonance imaging of urea transporter knockout mice shows renal pelvic abnormalities | |
| Song et al. | An Assessment of Band Keratopathy Depth With Anterior Segment Optical Coherence Tomography | |
| LaGrange et al. | The effect of sodium thiosulfate administration on nephrocalcinosis in a rat model | |
| Ha et al. | Double Infarcts in the Anterior and Posterior Cerebral Artery Territories. | |
| EP3331517A1 (fr) | Utilisation d'hydroxycarbamide pour prevenir la non-perfusion retinienne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20090417 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090417 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120731 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121022 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130108 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130401 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130408 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130606 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130613 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130708 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140401 |